EGFR inhibitors: Clinical results

Tumori

Volumn 1, Issue 6 SUPPL., 2002, Pages

  De Marinis, Filippo ^a   Nelli, Fabrizio ^a   D'Auria, Giuliana ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; GEMCITABINE; GROWTH FACTOR RECEPTOR; PACLITAXEL; PROTEIN; PROTEIN HER 1; PROTEIN HER 3; PROTEIN HER 4; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; TOPOTECAN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; LIVER DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRURITUS; RASH; RECEPTOR BLOCKING; SKIN TOXICITY; SOLID TUMOR; VOMITING;

EID: 0036836777     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/03008916020016s102     Document Type: Conference Paper

References (14)

1. Olayioye MA, Neve RM, Lane HA et al: The Erb signaling network: receptor heterodimerization in development and cancer. EMBO J, 19: 3159-3167, 2000.
2. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther, 82: 241-250, 1999.
3. Wells A: EGF receptor. Int J Biochem Cell Biol, 31: 637-643, 1999.
4. Wells A: The epidermal growth factor receptor (EGFR): a new target in carcer therapy. Signal, 1: 4-11, 2000.
5. Woodburn JR, Wakeling A, Kelly H et al: Preclinical studies with the oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 ('Iressa') demonstrate significant antitumor activity. Presented at the Signal Transduction Pathways and Regulation of Gene Expression as Therapeutic Targets Meeting, Luxembourg, January 26-29, 2000.
6. Ranson M, Hammond LA, Ferry D et al: ZD 1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumours: results of a phase I trial. J Clin Oncol, 20: 2240-2250, 2002.
7. S Negoro, K Nakagawa, M Fukuoka et al: Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumours. Proc Am Soc Clin Oncol, 20: abst 1292, 2001.
8. Baselga J, Herbst R, Lo Russo P et al: Continuous administration of ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumour types: evidence of activity and good tolerability. Proc Am Soc Clin Oncol, 19: 177a (abst 686), 2000.
9. Chen Z, Ke LD, Yuan XH et al: Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells. Anticancer Res, 20: 899-902, 2000.
10. Wosikowski K, Silverman JA, Bishop P et al: Reduced growth rate accompanied by aberrant epidermal growth factor receptor signalling in drug resistant human breast cancer cells. Biochim Acta, 1497: 215-226, 2000.
11. Miller VA, Johnson D, Heelan RT et al: A pilot trial demonstrates the safety of ZD1839 ('Iressa'), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 20: abst 1301, 2001.
12. Gonzalez-Larriba JL, Giaccone G, van Oosterom AT et al: ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemonaive patients with advanced solid tumours: final results of a phase I trial. Proc Am Soc Clin Oncol, 21: abst 376, 2002.
13. Fukuoka M, Yano S, Giaccone G et al: Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol, 21: abst 1188, 2002.
14. Kris MG, Natale RB, Herbst RS et al: A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol, 21: abst 1166, 2002.